Literature DB >> 28141677

Unique Inflammatory Bowel Disease Phenotype of Pediatric Primary Sclerosing Cholangitis: A Single-Center Study.

Henry Shiau1, Faith D Ihekweazu, Mansi Amin, Tatiana Fofanova, Tamir Miloh, Richard Kellermayer.   

Abstract

OBJECTIVES: In adults, primary sclerosing cholangitis (PSC), a cholestatic liver disease characterized by inflammation/fibrosis of intra/extrahepatic bile ducts, associates with a milder form of inflammatory bowel disease (IBD), particularly ulcerative colitis (UC). The pediatric PSC-IBD phenotype is less well characterized.
METHODS: We performed a retrospective, single-center study examining patients with PSC-IBD at Texas Children's Hospital between 2000 and 2015. IBD-phenotype (Modified Montreal Classification), medications, laboratory values, endoscopic records, and IBD-based hospital admissions were collected. PSC-UC phenotype was compared to UC, non-PSC patients (n = 95) from Texas Children's Hospital. Elevated gamma-glutamyl transpeptidase levels were compared to calprotectin levels and IBD-flare activity, that is, gastrointestinal symptoms resulting in office/emergency department visits or hospital admission.
RESULTS: Of 39 patients with PSC-IBD, 34 (87.2%) had UC (PSC-UC) and 5 (12.8%) had Crohn disease. Pancolitis was more common in PSC-UC than UC, non-PSC (96.3%, 64%, P = 0.0009). Patients with PSC-UC required less treatment with steroids (76.5%, 91.6%, P = 0.0326) or infliximab (8.8%, 37.9%, P = 0.0011), and fewer had at least 1 IBD-related hospital admission (32.4%, 63.2%, P = 0.0025) than UC, non-PSC. Progression to colectomy was significantly less (5.8%, 24.2%, P = 0.0223) in PSC-UC. Median diagnosis-to-colectomy time tended to be longer in PSC-UC (6.37, 2.5 years, P = 0.0792). In 2 smaller subsets, gamma-glutamyl transpeptidase did not correlate with calprotectin in PSC-UC (n = 11, P = 0.7922) and less strongly associated with IBD-flares in PSC-UC than UC, non-PSC (n = 33, n = 67; 15.2%, 41.8%, P = 0.0120).
CONCLUSIONS: Pediatric PSC appears to associate with milder pancolitic-UC. PSC and IBD activity do not appear to correlate. Our findings may provide useful information toward etiology and management of pediatric PSC-IBD.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28141677      PMCID: PMC5533626          DOI: 10.1097/MPG.0000000000001531

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  25 in total

1.  Abnormal Liver Biochemistry Is Common in Pediatric Inflammatory Bowel Disease: Prevalence and Associations.

Authors:  Pamela L Valentino; Brian M Feldman; Thomas D Walters; Anne M Griffiths; Simon C Ling; Eleanor M Pullenayegum; Binita M Kamath
Journal:  Inflamm Bowel Dis       Date:  2015-12       Impact factor: 5.325

2.  Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease.

Authors:  S K Bunn; W M Bisset; M J Main; B E Golden
Journal:  J Pediatr Gastroenterol Nutr       Date:  2001-02       Impact factor: 2.839

3.  Infliximab for induction and maintenance therapy for ulcerative colitis.

Authors:  Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

4.  Pediatric ulcerative colitis associated with autoimmune diseases: a distinct form of inflammatory bowel disease?

Authors:  Felipe Ordonez; Florence Lacaille; Danielle Canioni; Cecile Talbotec; Jean-Christophe Fournet; Nadine Cerf-Bensussan; Olivier Goulet; Jacques Schmitz; Frank M Ruemmele
Journal:  Inflamm Bowel Dis       Date:  2012-01-11       Impact factor: 5.325

5.  Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history.

Authors:  Mark Deneau; M Kyle Jensen; John Holmen; Marc S Williams; Linda S Book; Stephen L Guthery
Journal:  Hepatology       Date:  2013-08-13       Impact factor: 17.425

6.  A retrospective single-center review of primary sclerosing cholangitis in children.

Authors:  Tamir Miloh; Ronen Arnon; Benjamin Shneider; Frederick Suchy; Nanda Kerkar
Journal:  Clin Gastroenterol Hepatol       Date:  2008-10-30       Impact factor: 11.382

Review 7.  Primary sclerosing cholangitis associated with inflammatory bowel disease: an update.

Authors:  Roberta E Rossi; Dario Conte; Sara Massironi
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-02       Impact factor: 2.566

8.  Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis.

Authors:  Roy M Soetikno; Otto S Lin; Paul A Heidenreich; Harvey S Young; Michael O Blackstone
Journal:  Gastrointest Endosc       Date:  2002-07       Impact factor: 9.427

9.  Contrasting Pattern of Chronic Inflammatory Bowel Disease in Primary and Autoimmune Sclerosing Cholangitis.

Authors:  Ingvar Bjarnason; Bu Hayee; Polychronis Pavlidis; Charlotte Kvasnovsky; Astrid Scalori; Guy Sisson; Annika Charlesworth; Hizbullah Shaikh; Einar Bjornsson; Michael A Heneghan
Journal:  EBioMedicine       Date:  2015-09-02       Impact factor: 8.143

Review 10.  The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis.

Authors:  Paul Henderson; Niall H Anderson; David C Wilson
Journal:  Am J Gastroenterol       Date:  2013-05-14       Impact factor: 12.045

View more
  6 in total

Review 1.  The IBD and PSC Phenotypes of PSC-IBD.

Authors:  Amanda Ricciuto; Binita M Kamath; Anne M Griffiths
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

2.  Progression to colectomy in the era of biologics: A single center experience with pediatric ulcerative colitis.

Authors:  Faith D Ihekweazu; Tatiana Fofanova; Ryan Palacios; Avanthi Ajjarapu; Lina Karam; Adam M Vogel; J R Rodriguez; Richard Kellermayer
Journal:  J Pediatr Surg       Date:  2020-02-03       Impact factor: 2.545

Review 3.  Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence.

Authors:  Andrew Mertz; Nhu An Nguyen; Konstantinos H Katsanos; Ryan M Kwok
Journal:  Ann Gastroenterol       Date:  2019-01-15

Review 4.  Specific Features of Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.

Authors:  Fotios S Fousekis; Vasileios I Theopistos; Ioannis V Mitselos; Alexandros Skamnelos; Athanasios Kavvadias; Konstantinos H Katsanos; Dimitrios K Christodoulou
Journal:  J Clin Med Res       Date:  2019-01-05

Review 5.  Treatment of primary sclerosing cholangitis in children.

Authors:  Trevor J Laborda; M Kyle Jensen; Marianne Kavan; Mark Deneau
Journal:  World J Hepatol       Date:  2019-01-27

6.  Gut Microbiome of Children and Adolescents With Primary Sclerosing Cholangitis in Association With Ulcerative Colitis.

Authors:  Ramon V Cortez; Luana N Moreira; Marina Padilha; Mariana D Bibas; Ricardo K Toma; Gilda Porta; Carla R Taddei
Journal:  Front Immunol       Date:  2021-02-05       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.